Antigenicity and immunogenicity of inactivated poliovirus vaccine in combined vaccine trials

  • N. Ajjan
  • P. Saliou


In developed countries the use of OPV is associated with the risk of paralysis,, whereas in developing countries its use is associated with relative inefficacy.

  • Various studies demonstrate that the seroconversion rate and level of protective anti bodies induced by the E-IPV are higher than with the OPV. After 2 or 3 doses of E-IPV the proportion of subjects with detectable neutralizing antibodies are similar. The third dose is necessary however in order to increase the geometric mean titer of antibodies and thus the duration of immunity. A schedule with 2 doses may be useful in rural areas where there are no operational health delivery services.

  • The potential value of OPV in limiting wild virus circulation is contrabalanced by the higher and more liable production antibodies of E-IPV. The incorporation of at least one dose of E-IPV at the start of the immunization schedule increases humoral as well as local antibody production. The sequential or combined use of the E-IPV and OPV could reduce or even eliminate the risk of vaccine associated poliomyelitis and maintain a high degree of humoral and local immunity.


Seroconversion Rate Immunization Schedule Oral Poliovirus Vaccine Oral Polio Vaccine Inactivate Poliovirus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beale AJ (1990) Polio vaccines: time for a change in immunization policy. Lancet 335: 839–842PubMedCrossRefGoogle Scholar
  2. 2.
    Böttiger M (1984) long term immunity following vaccination with killed polio vaccine in Sweden, a country with no circulating poliovirus. Rev Infect Dis 6[Suppl]: 548–551CrossRefGoogle Scholar
  3. 3.
    Deming MS, Jaiteh OK, Otten MW et al (1992) Epidemic poliomyelitis in the Gambia following the control of poliomyelitis as an endemic disease. II clinical efficacy of trivalent oral polio vaccine. Am J Epidemiol 135: 393–408PubMedGoogle Scholar
  4. 4.
    Dhar R, Ogra PL (1985) Local immune responses. Br Med Bull 41: 28–33PubMedGoogle Scholar
  5. 5.
    Dick GWA, Dane OS, McAlister J, et al (1961) Vaccination against poliomyelitis with live virus vaccine. 7. Effect of previous Salk vaccination on virus excretion. Br Med J 2: 266PubMedCrossRefGoogle Scholar
  6. 6.
    Drucker (1987) Utilisation en milieu tropical d’un vaccin injectable concentré et inactivé contre la poliomyélite. Résultats sérologiques-3éme Séminaire International sur la Vaccina tion en Afrique. Ed Foundation Marcel Mérieux, 163–172Google Scholar
  7. 7.
    Drucker J, Soula G, Diallo, et al (1986) Evaluation of a new combined inactivated DPT Polio vaccine. Dev Biol Stand 65: 145–158PubMedGoogle Scholar
  8. 8.
    Faden H, Modlin JF, Thoms ML, et al (1990) Comparative evaluation of immunization with live attenuated and enhanced potency in activated trivalent poliovirus vaccines in childhood: systemic and local immune response. Infect Dis 162: 1291–1297CrossRefGoogle Scholar
  9. 9.
    Glezen WP, Lamb GA,Beiden EA, et al (1966) Quantitative relationship of pre-existing homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 83: 224–227PubMedGoogle Scholar
  10. 10.
    Grenier B, Hamza B, Biron G, et al (1984) Sero-immunity following vaccination in infants by an inactivated poliovirus vaccine prepared on Vero cells. Rev Infect Dis 6[Suppl]: 545–547CrossRefGoogle Scholar
  11. 11.
    Henry JL,Jaikaran ES, Davies JR Tomlinson AJH, et al (1966) A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living polio vaccine. J Hyg 64: 105CrossRefGoogle Scholar
  12. 12.
    Jaitech KO, Otten, Deming M (1986) Epidemic poliomyelitis in the Gambia. In progress report of Epidemiologic FindingsGoogle Scholar
  13. 13.
    JohnJ, Sevvakumar R, Balraj V et al (1987) Field studies using killed poliovirus vaccine. 3rd InternSeminar on immunization in Africa Collection -Foundation Marcel Mérieux 173–181Google Scholar
  14. 14.
    Kim Farley RJ, Rutherford G, Litchfiel D, et al (1984) Outbreak of paralytic poliomyelitis in Taiwan. Lancet 2: 1322–1324Google Scholar
  15. 15.
    Lapinleimu K, Stenvik M (1984) Experiences with polio vaccination and herd immunity in Finland. Dev Biol Stand 47: 241Google Scholar
  16. 16.
    Lasch E, Abed Y, Gerichter CB, et al (1983) Results of a program sucessfully combining live and killed polio vaccines. Israel J Med Sc 19: 1021–1023Google Scholar
  17. 17.
    Lepow ML, Warren RJ, Grayn et al (1961) Effect of Sabin type 1 poliomyelitis vaccine administered by month for newborn infants. N Engl J Med 284: 1071–1078CrossRefGoogle Scholar
  18. 18.
    Mugnus HV, Petersen I (1984) Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 6[Suppl]: 471–474CrossRefGoogle Scholar
  19. 19.
    Marine WM, Chin TDY, Gravelle CR (1962) Limitation of fecal and pharyngeal poliovirus excretion in Salk vaccinated children. A family study during a type 1 poliomyelitis epidemic. AmJ Hyg 173–195Google Scholar
  20. 20.
    McBean AM, Modlin JF (1987) Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 6: 881–887PubMedCrossRefGoogle Scholar
  21. 21.
    McBean AM, Thoms ML, Albrecht P, et al (1988) Serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am J Epidemiol 128: 615–628PubMedGoogle Scholar
  22. 22.
    Modlin JF, Onorato IM, McBean M, et al (1990) The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral polio. A J D C 144: 480–484Google Scholar
  23. 23.
    Montagnon B, Fanget B, Vincent Falquet JC (1984) Industrial scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 6[Suppl 2]: 341–344CrossRefGoogle Scholar
  24. 24.
    Ogra PL (1984) Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis 6[Suppl 2]: 361–368CrossRefGoogle Scholar
  25. 25.
    Ogra PL, Faden HS, Abraham R (1991) Effect of prior immunity on the shedding of virulent revertant virus in faeces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164: 191–194PubMedCrossRefGoogle Scholar
  26. 26.
    Onorato I, Modlin J, McBean M, et al (1991) Mucosal immunity induced by enhanced potency, inactivated and oral polio vaccines. J Infect Dis 163: 1–6PubMedCrossRefGoogle Scholar
  27. 27.
    Otten MW, Deming MS, Jaitech KO, et al (1992) Epidemic poliomyelitis in the Gambia following the control of poliomyelitis as an endemic disease. I Descriptive Findings. Am J Epidemiol 135: 381–392PubMedGoogle Scholar
  28. 28.
    Patriarca PA, Laender F, Plameira G, et al (1988) Randomized trial of alternative formulation of oral polio vaccines in Brazil. Lancet 8583: 429–433CrossRefGoogle Scholar
  29. 29.
    Patriarca PA, Wright PF, John TJ, et al (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev Infect Dis 13: 926–939PubMedCrossRefGoogle Scholar
  30. 30.
    Plotkin SA, Katz M, Brown RE, et al (1966) Oral poliovirus vaccination in newborn African infants: the inhibitory effect of breast feeding. Am J Dis Child 111: 27–30PubMedGoogle Scholar
  31. 31.
    Roberston SE, Traverso HP, Drucker JA, et al (1988) Clinical efficacy of a new enhanced potency, inactivated poliovirus vaccine. Lancet 1: 897–899Google Scholar
  32. 32.
    Salk D, Van Wezel AL, Salk J (1984) Induction of long term immunity to paralytic poliomyelitis by use of non infectious vaccine. Lancet 2: 1317–1321PubMedCrossRefGoogle Scholar
  33. 33.
    Schatzmayr HG, Maurice Y, Fujita M, et al (1986) Serologic evaluation of poliomyelitis oral and inactivated vaccines in an urban low income population at Rio de Janeiro Brazil. Vaccine 4: 111–113PubMedCrossRefGoogle Scholar
  34. 34.
    Selvakumar R, Jacob JT (1987) Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 5: 141–144PubMedCrossRefGoogle Scholar
  35. 35.
    Simoes EAF, Padminibi, Steinaoff MC, et al (1985) Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 139: 977–980PubMedGoogle Scholar
  36. 36.
    Strebel PM, Sutter RW, Cochi SL, et al (1992) Epidemiology of poliomyelitis in United States one decade after the last reported case of indigenne wild virus associated disease. Vlin Infect Dis 14: 568–579CrossRefGoogle Scholar
  37. 37.
    Swartz TA, Handher R, Stoeckel P, et al (1989) Immunologie memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 5: 143–145PubMedCrossRefGoogle Scholar
  38. 38.
    Sutter RW, Patriarca PA, Brogan S, et al (1991) Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 338:715–720PubMedCrossRefGoogle Scholar
  39. 39.
    Tulchinsky T, Yehia Abed MPH, Shaheen S (1989) A ten year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas. AJPH 79: 1648–1651CrossRefGoogle Scholar
  40. 40.
    Zhaori G, Sun M, Faden HS, et al (1989) Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specification after immunization with live or inactivated poliovirus vaccines. J Infect Dis 159: 1018–1021PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • N. Ajjan
    • 1
  • P. Saliou
    • 1
  1. 1.Pasteur Mérieux Serums and VaccinesMarnes-La-CoquetteFrance

Personalised recommendations